Most startup pitches to defense agencies go nowhere. The technology sounds promising in a slide deck, perhaps even plausible in a lab notebook, but the Pentagon has heard it all before—and usually files it away.
Swaza, a Mountain View biotech founded by a handful of scientists from Stanford, MIT, and Harvard, somehow cleared that bar. And then cleared it twice more.
The company announced a $400,000 seed round from Istanbul-based Techventure VC on March 30, 2026, adding a modest cushion of private capital to what's become an unusual trifecta of government validation. Before a single human trial, Swaza has secured a contract with BARDA, been selected for a program by NATO DIANA, and signed a Space Act Agreement with NASA's Johnson Space Center. For a four-year-old startup with fewer than ten employees, that's the kind of institutional backing that either signals something genuinely novel—or sets up a very public reckoning if the science doesn't pan out.
At the heart of it all: a nanofluid the company claims can deliver oxygen therapy through an ordinary hospital nebulizer, no tanks or ventilators required.
The Science, or at Least the Pitch
SWAZA-1, as the lead product is called, isn't oxygen in any conventional sense. APEX Ventures describes the formulation as relying on modified liposomes—tiny lipid bubbles—that carry oxygen molecules through the mucus and fluid barriers clogging the lungs of patients in acute respiratory distress. The liposomes shuttle their cargo to the alveoli, those delicate air sacs where gas exchange happens, while simultaneously binding carbon dioxide for removal on exhalation.
It's an elegant theory. Whether it works in humans is another question entirely.
The target conditions read like a tour of emergency medicine's worst-case scenarios: acute respiratory distress syndrome, severe pneumonia, smoke inhalation, drowning. Mortality rates in these cases often land between 30% and 40%, and the standard playbook leans heavily on mechanical ventilation—invasive, resource-intensive, and not always available when minutes matter. Swaza's pitch is that the nanofluid could serve as an early bridge, buying time before a patient deteriorates to the point of intubation. If it works, the applications extend beyond hospital ICUs into aeromedical transport, disaster zones, and pre-hospital care—anywhere traditional oxygen infrastructure is scarce or impractical.
CEO Niki V. Santo told NATO DIANA in January that first-in-human studies are in the works, though no public trial registrations have surfaced yet. That gap between preparation and execution is common in early-stage biotech, but it's also where optimism meets reality.
Government Contracts as Venture Capital
BARDA, the federal agency tasked with preparing for public health emergencies, awarded Swaza a contract valued at up to $745,500 in June 2023. So far, $372,800 has been obligated, funding work scheduled to run through October 2025. For context, BARDA's portfolio tilts toward technologies with clear pathways to real-world deployment, often in crisis scenarios.
NATO's Defense Innovation Accelerator for the North Atlantic, or DIANA, selected Swaza for its Phase 2 program and featured the company in a January 2026 spotlight. It's the sort of nod that opens doors in European defense markets, though translating endorsements into revenue is rarely straightforward.
And then there's NASA. The Johnson Space Center signed a Space Act Agreement with Swaza in March to explore statistical modeling for exploration-class missions. On the surface, it's an odd pairing—respiratory care for astronauts doesn't immediately scream "urgent need"—but extreme environments have a way of exposing the limits of conventional medical gear. If Swaza's nanofluid can function in microgravity or on a cramped spacecraft, that's a data point worth having.
Taken together, these partnerships suggest that multiple agencies see something worth exploring. But government interest and clinical success are not the same thing, and the leap from contract work to market-ready product has humbled plenty of biotechs before.
The Funding Landscape
Techventure's $400,000 investment, led by founding partners Sedat and Sena Avşar, is modest even by seed-stage standards. The investors cited Swaza's traction with BARDA and DIANA as key factors, a common refrain in biotech where early validation—regulatory, governmental, or otherwise—carries outsize weight.
Swaza's earlier backers include APEX Ventures and R42 Group, according to portfolio listings, and the company holds membership in the Medical Technology Enterprise Consortium. It was also selected as a Showcase Company at the American Thoracic Society's 2025 Respiratory Innovation Summit, another credential that suggests the scientific community is at least paying attention.
Beyond SWAZA-1, the company is positioning its nanofluid platform for wound care, burns, and trauma—an expansion that hints at broader regenerative medicine ambitions. Whether that's visionary or a distraction from the core respiratory play depends largely on whether the lead product delivers.
What Comes Next
According to DIANA's January profile, the nanofluid is formulated from FDA-established materials and remains stable at room temperature—no cold chain, no bulky storage requirements. If those claims hold, the portability advantage alone could shift how emergency oxygen is deployed. But "if" is doing a lot of work in that sentence.
First-in-human trials will be the inflection point. Regulatory agencies will want to see not just safety, but evidence that the nanofluid meaningfully improves outcomes compared to standard care. Investors will watch for signals that the technology can scale beyond niche military or disaster applications into broader clinical adoption. And competitors—assuming they're not already working on something similar—will take note if Swaza's approach gains traction.
For now, the company occupies a curious middle ground: too validated to dismiss, too unproven to bet the farm on. The government contracts offer a cushion that pure venture-backed startups rarely enjoy, but they also come with expectations. Agencies that fund early-stage technology don't do it for charity—they want solutions that work when the stakes are highest.
Swaza's founders seem to understand that. Whether their nanofluid can deliver on the promise is a question that won't be answered in a pitch deck or a press release. It'll be answered in a clinic, with real patients, under conditions that leave no room for optimistic projections.
And that's exactly as it should be.
